Again, CD47KO tumor cell vaccination resulted in a significantly increased frequency of CD11c+SIRPα+ (F4/80−CD64−) DCs (Fig. 5b) and their expression of MHC class II I-Ab (Fig. 5c) compared to vaccination with WT tumor cells. This evidence concerns the gene SIRPA and neoplasm.